Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Von Hippel-Lindau Syndrome
NCT00330564Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2006
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in von Hippel-Lindau syndrome (VHL), sponsored by University of Texas MD Anderson Cancer Center. Started May 2006; status: terminated.
02
Drugs
sunitinib
03
Conditions
von Hippel-Lindau syndrome (VHL)
Beyond the preview
Go deeper on NCT00330564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00330564.